Actively Recruiting
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Led by University of Pennsylvania · Updated on 2026-03-03
10
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
CONDITIONS
Official Title
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed, written informed consent
- Male or female patients age 63 18 years
- Co-enrolled in a University of Pennsylvania-Sponsored, CCI-Initiated CAR T cell clinical trial
- Subjects of reproductive potential must agree to use acceptable birth control methods as described in the protocol
You will not qualify if you...
- Pregnant or nursing (lactating) women
- Known hypersensitivity to the active substance or one of the excipients of the investigational product(s)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here